CDC25C and acute myeloid leukemia: These overall results suggest that the antiproliferative effects of both CDC25 and PI3K/Akt/mTOR inhibition are strongest for AML cells having favorable cytogenetic abnormalities and/or showing less signs of differentiation, judged from the high expression of the CD34 stem cell marker and/or having few morphological signs of differentiation (i.e., FAB classification FAB-0/1/2; absent monocytic differentiation).